@j@i CΘOCFirst, Second and Corresponding Author*Μέj
2010N
Kaji H*, Yamauchi M, Yamaguchi T, Shigematsu T, Sugimoto T. Mild renal
dysfunction is a risk factor for a decrease in bone mineral density and
vertebral fractures in Japanese postmenopausal women. J Clin Endocrinol Metab. 95: 4635-4642, 2010.
Kuroki Y, Kaji H*, Kawano S, Kanda F, Takai Y, Kajikawa M, Sugimoto T.
Prospective short-term effects of glucocorticoid treatment on glucose and
lipid metabolism in Japanese. Intern Med. 49: 897-902, 2010.
Inoue Y, Hisa I, Seino S, Kaji H*. Alendronate induces mineralization in mouse osteoblastic MC3T3-E1 cells: regulation of mineralization-related genes. Exp Clin Endocrinol Diabet. 118: 719-723, 2010.
Kaji H*, Yamauchi M, Yamaguchi T, Sugimoto T. Urinary deoxypyridinoline
is a BMD-independent marker for prevalent vertebral fractures in postmenopausal
women treated with glucocorticoid. Osteoporos Int. 21: 1585-1590, 2010.
Kaji H*, Kuroki Y, Murakawa Y, Funakawa I, Funasaka Y, Kanda F, Sugimoto
T. Effect of alendronate on bone metabolic indices and bone mineral density
in patients treated with high-dose glucocorticoid: a prospective study.
Osteoporos Int. 21: 1565-1571, 2010.
Kaji H*, Hisa I, Inoue Y, Sugimoto T. Low density lipoprotein-cholesterol levels affect vertebral fracture risk in female patients with primary hy perparathyroidism. Exp Clin Endocrinol Diabetes. 118: 371-376, 2010.
2009N
Bando H, Hashimoto N, Hirota Y, Sakaguchi K, Hisa I, Inoue Y, Imanishi
Y, Seino S,@Kaji H*. A case of severe hypophosphatemic osteomalacia with
Faconi syndrome, renal tubular acidosis, vitamin D deficiency and primary
biliary cirrhosis. Intern Med. 48: 353-358, 2009.
Kaji H*, Hisa I, Inoue Y, Naito J, Sugimoto T, Kasuga M. Analysis of factors
affecting an increase in bone mineral density at lumbar spine by bisphosphonates
in postmenopausal osteoporosis. J Bone Miner Metab. 27: 76-82, 2009.
Inoue Y, Canaff L, Hendy GN, Hisa I, Sugimoto T, Chihara K, Kaji H*. Role of Smad3, acting independently of transforming growth factor-beta, in the early induction of Wnt-beta-catenin signaling by parathyroid hormone in mouse osteoblastic cells. J Cell Biochem. 108: 285-294, 2009.
Kaji H*, Yamauchi M, Nomura R, Sugimoto T. Two-year longitudinal changes
in cortical bone geometry in postmenopausal women with mild primary hyperparathyroidism.
Exp Clin Endocrinol Diabet. 117: 633-636, 2009.
2008N
Inoue Y,@Kaji H*, Hisa I, Tobimatsu T, Naito J, Iu MF, Sugimoto T, Chihara
K. Vitamin D status affects bone mineral density in postmenopausal patients
with primary hyperparathyroidism. Endocr J. 55: 57-65, 2008.
Kaji H*, Yamauchi M, Chihara K, Sugimto T. Relationship between endogenous parathyroid hormone and bone metabolism in female patients treated with glucocorticoid. Horm Metab Res. 40: 60-65, 2008.
Kuroki Y, Kaji H, Kawano S, Kanda F, Takai Y, Kajikawa M, Sugimoto T. Short-term
effects of glucocorticoid therapy on biochemical markers of bone metabolism
in Japanese patients: a prospective study. J Bone Miner Metab. 26: 271-278, 2008.
Kaji H*, Yamauchi M, Chihara K, Sugimoto T. Glucocorticoid excess affects
bone geometry in premenopausal women, but not in postmenopausal women. Calcif Tissue Int. 82:182-190, 2008.
Kaji H*, Yamauchi M, Nomura R, Sugimoto T. Improved peripheral cortical bone geometry after surgical treatment of primary hyperparathyroidism in postmenopausal women. J Clin Endocrinol Metab. 93: 3045-3050, 2008.
Kaji H*, Naito J, Inoue Y, Sowa H, Sugimoto T, Chihara K. Statin suppresses
cell apoptosis through TGF-beta-Smad3 pathway in osteoblastic cells. Horm Metab Res. 40: 746-751, 2008.
Hisa I, Kaji H*, Inoue Y, Sugimoto T, Chihara K. Plasma fasting glucose
levels are related to bone mineral density in postmenopausal women with
primary hyperparathyroidism. Int J Clin Exp Med. 1: 319-326, 2008.
2006N
Kaji H*, Naito J, Sowa H, Sugimoto T, Chiahra K. Serum soluble factors
induce the proliferation, alkaline phosphatase activity and transforming
growth factor-beta signal in osteoblastic cells in the patient with hepatitis
C-associated osteosclerosis. Exp Clin Endocrinol Diabetes. 114:599-604, 2006.
Kaji H*, Iu MF, Naito J, Sugimoto T, Chihara K. A case of primary hyperparathyroidism
with the marked change of bone mimeral density and bone morphometry after
parathyroidectomy. J Bone Miner Metab. 24: 349-352, 2006.
Kaji H*, Tobimatsu T, Naito J, Iu MF, Yamauchi M, Sugimoto T, Chihara K.
Body composition and vertebral fracture risk in female patients treated
with glucocorticoid. Osteoporos Int. 17: 627-633, 2006.
Kaji H*, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J. 53: 27-34, 2006.
Naito J, Kaji H*, Sowa H, Kitazawa R, Kitazawa S, Tsukada T, Hendy GN,
Sugimoto T, Chihara K. Expression and functional analysis of menin in a
multiple endocrine neoplasia type I (MENI) patient with somatic loss of
heterozygosity in chrmosome 11q13 and unidentified germline mutation of
the MENI gene. Endocrine. 29: 485-490, 2006.
Tobimatsu T, Kaji H*, Sowa H, Naito J, Hendy GN, Sugimoto T, Chihara K.
Parathyroid hormone increases beta-catenin levels through Smad3 in mouse
osteoblastic cells. Endocrinology. 147: 2583-2590, 2006.
Kaji H*, Naito J, Sowa H, Sugimoto T, Chihara K. Smad3 differently affects osteoblast differentiation dependent upon differentiation stage in mouse osteoblastic cells. Horm Metab Res. 38: 740-745, 2006.
Kaji H*, Nomura R, Yamauchi M, Chihara K, Sugimoto T. The usefulness of
bone metabolic indices for the prediction of changes in bone mineral density
after parathyroidectomy in patients with primary hyperparathyroidism. Horm Metab Res. 38: 411-416, 2006.
2005N
Naito J, Kaji H*, Sowa H, Hendy GN, Sugimoto T, Chihara K. Menin suppresses
osteoblast differentiation by antagonizing the AP-1 factor, JunD. J Biol Chem. 280:4785-4791, 2005.
Iu MF, Kaji H*, Sowa H, Naito J, Sugimoto T, Chihara K. Dexamethasone suppresses Smad3 pathway in osteoblastic cells. J Endocrinol. 185:131-138, 2005.
Kaji H*, Kanatani M, Sugimoto T, Chihara K. Statins modulate the levels
of osteoprotegerin/receptor activator of NFkB ligand mRNA in mouse bone
cell cultures. Horm Metab Res. 37: 589-592, 2005.
Iu MF, Kaji H*, Naito J, Sowa H, Sugimoto T, Chihara K. Low-dose parathyroid
hormone and estrogen reverse alkaline phosphatase activity suppressed by
dexamethasone in mouse osteoblastic cells. J Bone Miner Metab. 23: 450-455, 2005.
Kaji H*, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fractures in female patients with primary hyperparathyroidism. Eur J Endocrinol. 153:373-378, 2005.
Kaji H*, Kosaka R, Yamauchi M, Kuno K, Chihara K, Sugimoto T. Effects of
age, grip strength and smoking on forearm volumetric bone mineral density
and bone geometry by peripheral quantitative computed tomography: comparisons
between female and male. Endocr J. 52: 659-666, 2005.
2004N
Sowa H, Kaji H, Kitazawa R, Kitazawa S, Tsukamoto T, Yano S, Tsukada T,
Canaff L, Hendy GN, Sugimoto T, Chihara K. Menin inactivation leads to
loss of transforming growth factor beta inhibition of parathyroid cell
proliferation and parathyroid hormone secretion. Cancer Res. 64:2222-2228, 2004.
Sowa H, Kaji H, Hendy GN, Canaff L, Komori T, Sugimoto T, Chihara K. Menin is required for bone morphogenetic protein 2- and transforming growth factor beta-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Biol Chem. 279:40267-40275, 2004.
Chen Q, Kaji H, Kanatani M, Sugimoto T, Chihara K. Testosterone increases
osteoprotegerin mRNA expression in mouse osteoblast cells. Horm Metab Res. 36:674-678, 2004.
2003N
Sowa H, Kaji H, Canaff L, Hendy GN, Tsukamoto T, Yamaguchi T, Miyazono
K, Sugimoto T, Chihara K. Inactivation of menin, the product of the multiple
endocrine neoplasia type 1 gene, inhibits the commitment of multipotential
mesenchymal stem cells into the osteoblast lineage. J Biol Chem. 278:21058-21069, 2003.
Kaji H*, Hattori S, Sekita K, Sugimoto T, Chihara K. Factors affecting bone mineral density in hemodialysis patients with diabetic nephropathy. Endocr J. 50:127-133, 2003.
Sowa H, Kaji H, Iu MF, Tsukamoto T, Sugimoto T, Chihara K. Parathyroid
hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action
of transforming growth factor beta in osteoblasts. J Biol Chem. 278:52240-52252, 2003.
Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto
T, Chihara K. Effects of an excess and a deficiency of endogenous parathyroid
hormone on volumetric bone mineral density and bone geometry determined
by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab. 88:4655-4658, 2003.
Chen Q, Kaji H, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Yamaguchi T, Kobayashi A, Sugimoto T, Chihara K. Trial to predict malignancy of affected parathyroid glands in primary hyperparathyroidism. Endocr J. 50:527-534, 2003.
2002N
Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Smad3 promotes alkaline
phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells.
J Bone Miner Res. 17:1190-1199, 2002.
Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Activations of ERK1/2
and JNK by transforming growth factor beta negatively regulate Smad3-induced
alkaline phosphatase activity and mineralization in mouse osteoblastic
cells. J Biol Chem. 277:36024-36031, 2002.
Kaji H*, Suzuki M, Yano S, Sugimoto T, Chihara K, Hattori S, Sekita K. Risk factors for hip fracture in hemodialysis patients. Am J Nephrol. 22:325-331, 2002.
Sugimoto T, Kaji H, Nakaoka D, Yamauchi M, Yano S, Sugishita T, Baylink
DJ, Mohan S, Chihara K. Effect of low-dose of recombinant human growth
hormone on bone metabolism in elderly women with osteoporosis. Eur J Endocrinol. 147:339-348, 2002.
2001N
Chen Q, Kaji H, Sugimoto T, Chihara K. Testosterone inhibits osteoclast
formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 491:91-93, 2001.
Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A. 98:3837-3842, 2001.
Kaji H, Sugimoto T, Nakaoka D, Okimura Y, Kaji H, Abe H, Chihara K. Bone
metabolism and body composition in Japanese patients with active acromegaly.
Clin Endocrinol. 55:175-181, 2001.
2000NΘO
Kaji H, Canaff L, Goltzman D, Hendy GN. Cell cycle regulation of menin
expression. Cancer Res. 59:5097-5101, 1999.
Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Chihara K. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2. J Bone Miner Res. 12:734-741, 1997.
Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Nasu M, Chihara K. Insulin-like
growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid
hormone. J Cell Physiol. 172:55-62, 1997.
Kaji H, Sugimoto T, Kanatani M, Fukase M, Kumegawa M, Chihara K. Prostaglandin
E2 stimulates osteoclast-like cell formation and bone-resorbing activity
via osteoblasts: role of cAMP-dependent protein kinase. J Bone Miner Res. 11:62-71, 1996.
Kaji H, Sugimoto T, Kanatani M, Nasu M, Chihara K. Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathway. Endocrinology. 137:2217-2224, 1996.
Kaji H, Sugimoto T, Kanatani M, Chihara K. High extracellular calcium stimulates
osteoclast-like cell formation and bone-resorbing activity in the presence
of osteoblastic cells. J Bone Miner Res. 11:912-920, 1996.
Kaji H, Sugimoto T, Kanatani M, Fukase M, Kumegawa M, Chihara K. Retinoic
acid induces osteoclast-like cell formation by directly acting on hemopoietic
blast cells and stimulates osteopontin mRNA expression in isolated osteoclasts.
Life Sci. 56:1903-1913, 1995.
Kaji H, Sugimoto T, Kanatani M, Kano J, Fukase M, Chihara K. Effect of retinoic acid on the proliferation and alkaline phosphatase activity of osteoblastic MC3T3-E1 cells by modulating the release of local regulators from monocytes. Exp Clin Endocrinol Diabetes. 103:297-302, 1995.
Kaji H, Sugimoto T, Kanatani M, Fukase M, Chihara K. Carboxyl-terminal
peptides from parathyroid hormone-related protein stimulate osteoclast-like
cell formation. Endocrinology. 136:842-848, 1995.
Kaji H*, Sugimoto T, Kanatani M, Miyauchi A, Kimura T, Sakakibara S, Fukase
M, Chihara K. Carboxyl-terminal parathyroid hormone fragments stimulate
osteoclast-like cell formation and osteoclastic activity. Endocrinology. 134:1897-1904, 1994.
Kaji H*, Sugimoto T, Miyauchi A, Fukase M, Tezuka K, Hakeda Y, Kumegawa M, Chihara K. Calcitonin inhibits osteopontin mRNA expression in isolated rabbit osteoclasts. Endocrinology. 135:484-487, 1994.
Kaji H*, Sugimoto T, Kanatani M, Fukase M, Chihara K. Involvement of dual
signal transduction systems in the stimulation of osteoclast-like cell
formation by parathyroid hormone and parathyroid hormone-related peptide.
Biochem Biophys Res Commun. 194:157-162, 1993.
Kaji H*, Sugimoto T, Fukase M, Chihara K. Role of dual signal transduction
systems in the stimulation of bone resorption by parathyroid hormone-related
peptide. The direct involvement of cAMP-dependent protein kinase. Horm Metab Res. 25:421-424, 1993.
Kaji H*, Sugimoto T, Kanatani M, Fukase M. The activation of cAMP-dependent protein kinase is directly linked to the stimulation of bone resorption by parathyroid hormone. Biochem Biophys Res Commun. 182:1356-1361, 1992.